RSV

Nirsevimab substantially reduced hospitalizations of babies from late September to late December 2023 in Galicia, according to a study published in The Lancet Infectious Diseases. This monoclonal antibody is administered to babies to prevent lower respiratory tract illness caused by respiratory syncytial virus (RSV). In Galicia, over 9 out of 10 babies received nirsevimab, which, according to the research, reduced the risk of hospitalizations for RSV-related respiratory illness by over 80%.

The NEJM publishes the results of a phase III clinical trial conducted by GSK that had to be suspended due to a safety signal. The study shows that newborns of vaccinated mothers had a lower risk of experiencing severe events associated with the respiratory syncytial virus (RSV), but also a higher risk of being born prematurely.

The European Medicines Agency (EMA) has recommended marketing authorisation in the European Union for Abrysvo vaccine to protect against respiratory syncytial virus (RSV) disease in infants up to six months of age. It is the first vaccine of its kind indicated for passive immunisation of newborns through administration to the mother during pregnancy. It is also indicated for people over 60 years of age. The European Commission now has to decide on its EU-wide marketing authorisation.

A journal article published in the BMJ discusses the potential adverse effects associated with GSK and Pfizer's RSV vaccines in the face of a possible increase in preterm births and argues for further study of the risks and benefits of the drug.

The European Medicines Agency (EMA) has recommended marketing authorisation in the European Union for Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in babies and infants. The agency recommends it during its first RSV season. The European Commission now has to decide on its marketing authorisation across the EU.